University of California, San Francisco

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of California, San Francisco sits in the top decile of US sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count).

1,713 total trials 272 currently recruiting 1130 completed early-phase tilt top decile by trial count

University of California, San Francisco: 1,713 sponsored US clinical trials, 272 recruiting.

University of California, San Francisco sponsors 1,713 registered US clinical trials on ClinicalTrials.gov, 272 of them currently recruiting, and 1,130 completed. 196 of these trials are in Phase 3-4 (later-stage) and 359 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 18 trials.

Top-decile sponsor footprint

University of California, San Francisco ranks in the top decile of sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 56/100

1,130 of 1,305 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,713 total, page 20 of 35

COMPLETED Phase 1

Donor-Alloantigen-Reactive Regulatory T Cell (darTreg) Therapy in Renal Transplantation (The ONE Study )

NCT02244801

COMPLETED NA

Enhancing PrEP in Community Settings (EPIC)

NCT02371525

COMPLETED NA

Mindfulness Based Stress Reduction for Older Adults With HIV Associated Neurocognitive Disorders

NCT02936401

TERMINATED Phase 2

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

NCT02587650

COMPLETED NA

Decision Support Tools for Men With Prostate Cancer- Clinical & Lifestyle Model

NCT02451345

COMPLETED NA

Care Ecosystem: Navigating Patients and Families Through Stages of Care

NCT02213458

COMPLETED NA

Paired Integrative Home Exercise for Seniors With Dementia and Their Caregivers (PairedPLIE)

NCT02403752

COMPLETED NA

Group Acupuncture Treatment Effects for Painful Diabetic Neuropathy (GATE-PDN)

NCT02104466

COMPLETED Phase 4

Uterotonic Prophylaxis Trial

NCT02408965

COMPLETED NA

National Comprehensive Cancer Network (NCCN) Decision Support Tool for Patients With NSCLC

NCT03982459

COMPLETED NA

Pilot #2 of Social Network Intrauterine Contraceptive (IUC) Intervention

NCT02242890

COMPLETED Phase 4

A Prospective Analysis of Preoperative Fascia Iliaca Block for Hip Arthroscopy

NCT02623361

TERMINATED Phase 1

Rosuvastatin Interethnic PK Study

NCT02215174

COMPLETED

Pilot Study of Coil Arrays in Patients With Advanced Solid Tumor Malignancies

NCT02390011

COMPLETED NA

Early Limited Formula for Treating Lactation Concerns

NCT02313181

COMPLETED NA

Lessening Incontinence Through Low-impact Activity

NCT02342678

COMPLETED

Online Neuropsychological Test Validation Project With Imaging Pilot

NCT02486250

COMPLETED NA

MoTHER Buddy Program

NCT02338765

COMPLETED NA

Paleo Versus Healthy ADA Diets for Treatment of Polycystic Ovarian Syndrome (PCOS)

NCT02190097

TERMINATED NA

TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve

NCT02147301

COMPLETED Phase 4

Mortality Reduction After Oral Azithromycin: Mortality Study

NCT02047981

COMPLETED

Tacrolimus Adjustment by NFAT-related Gene Expression in Lung Allograft Recipients.

NCT02278952

COMPLETED NA

Diabetes Prevention Among Post-partum Women With History of Gestational Diabetes

NCT02240420

TERMINATED Phase 4

A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal

NCT02317276

COMPLETED NA

Aides in Respiration Health Coaching for COPD

NCT02234284

COMPLETED NA

PilAm Go4Health Weight Loss Program to Prevent Heart Disease

NCT02290184

COMPLETED NA

Fit and Trim for Diabetes Prevention

NCT02278939

COMPLETED Phase 4

Mortality Reduction After Oral Azithromycin: Morbidity Study

NCT02048007

COMPLETED Phase 1

The Effects of Rifampin on the Pharmacokinetics of Rosuvastatin

NCT02106767

COMPLETED Phase 1

Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma

NCT02022644

TERMINATED

Evaluation of Rectal Cancer Treatment Response Using PET/MRI

NCT02233595

COMPLETED NA

Program to Overcome Pelvic Pain With Yoga

NCT02261740

COMPLETED NA

Tobacco Status Project: Social Media Intervention for Young Adult Smokers

NCT02207036

COMPLETED NA

Patient-Centered Support for Contraceptive Decision-Making

NCT02078713

COMPLETED NA

Primary Care Beverage Study

NCT02257203

COMPLETED NA

Fatigue Management in HIV

NCT02126007

COMPLETED Phase 1

Fecal Microbiota Transplantation in HIV

NCT02256592

COMPLETED NA

The OneFreeze Study

NCT02217254

TERMINATED Phase 1

Dichoptic Virtual Reality Therapy for Amblyopia in Adults

NCT02246556

COMPLETED NA

Molecular Profiling for Individualized Treatment Plan for DIPG

NCT02274987

TERMINATED Phase 2

Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer

NCT02215161

COMPLETED Phase 1

Effects of Non-steroidal Anti-inflammatory Drugs (NSAIDS) on Acclimatization to High Altitude

NCT02233582

COMPLETED NA

Reducing Distress And Improving Glycemic Control In Adults With Type 1 Diabetes

NCT02175732

COMPLETED

Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)

NCT02365922

COMPLETED NA

Gender-Responsive Drug Use Treatment for Juvenile Justice Girls

NCT02293057

COMPLETED Phase 3

Administration of Follicle-stimulating Hormone (FSH) and Low Dose Human Chorionic Gonadotropin (hCG) for Oocyte Maturity While Decreasing hCG Exposure in In Vitro Fertilization (IVF) Cycles

NCT02310919

COMPLETED NA

Preparing Spanish-speaking Older Adults for Advance Care Planning and Medical Decision Making (PREPARE)

NCT02072941

COMPLETED NA

Controlling Urgency Through Relaxation Exercises

NCT02202031

COMPLETED

Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma

NCT02060890

COMPLETED Phase 1

Vaporized Cannabis for Chronic Pain Associated With Sickle Cell Disease

NCT01771731

← Previous Page 20 of 35 Next →

Phase Distribution

PhaseTrial count
Phase 1 193
Phase 2 166
Phase 3 44
Phase 4 152

What is open in the University of California, San Francisco pipeline

272 recruiting of 1,713 indexed (16% open); 1,130 completed (66%).

Phase mix: 196 late (III/IV) vs 359 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (18 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of California, San Francisco: open-pipeline peers nationwide

Peers matched on 1,713 registered trials and 16% open enrollment, not the therapeutic-area sidebar.

University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 5%10%15%20% Total trials Recruiting share University of California, San FranciscoDuke UniversityStanford UniversityVA Office of Research and DevelopmentPfizerUniversity of OregonFox Chase Cancer CenterYoungstown State UniversityECOG-ACRIN Cancer Research Group
University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,713 trials (± recruiting share)

Sponsors near 16% open enrollment (± trial volume)

What to do with this University of California, San Francisco page

1,713 registered trials is a research-attention snapshot, not an endorsement of University of California, San Francisco or any single study.

  • 272 of University of California, San Francisco's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition University of California, San Francisco studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of California, San Francisco pipeline card: 1,713 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.